New Delhi, May 9 -- Amid growing concerns about potential US import tariffs on pharmaceuticals, Indian generics giant Dr. Reddy's Laboratories is taking steps to secure its supply chain for key products entering the American market, chief executive Erez Israeli said.

Also Read | Will Natco and Dr. Reddy's bet on weight-loss drug Ozempic's copy pay off?

"The main concern is a potential disruption of supply.most of the activities that we are doing now is working closely with the customers and creating the relevant inventory, service, orders and everything that allows us to give good service," said Israeli, adding that "service is our number one priority".

Israeli was speaking at a media briefing on Friday after the company posted its Q4 ...